ALC.SW · EBS · Healthcare
Alcon Inc.
Also onConsensus Drift
Implied value per share
CHF 75.61
Market price
CHF 53.66
Implied upside
+40.9%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · USD model at 0.8218
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 11.0bn | USD 11.7bn | USD 12.4bn | USD 13.2bn | USD 14.0bn | +6.1% |
| EBIT | USD 1.3bn | USD 1.3bn | USD 1.4bn | USD 1.5bn | USD 1.6bn | +6.1% |
| NOPAT | USD 1.1bn | USD 1.1bn | USD 1.2bn | USD 1.3bn | USD 1.4bn | +6.1% |
| Add depreciation & amortisation | USD 1.4bn | USD 1.5bn | USD 1.6bn | USD 1.7bn | USD 1.8bn | +6.1% |
| Less capital expenditure | USD -846.2m | USD -897.5m | USD -951.9m | USD -1.0bn | USD -1.1bn | +6.1% |
| Less increase in working capital | USD -308.9m | USD -327.7m | USD -347.5m | USD -368.6m | USD -391.0m | +6.1% |
| Free cashflow to firm | USD 1.3bn | USD 1.4bn | USD 1.5bn | USD 1.6bn | USD 1.7bn | +6.1% |
| Discount factor | 0.9767 | 0.9316 | 0.8887 | 0.8477 | 0.8086 | - |
| Present value | USD 1.3bn | USD 1.3bn | USD 1.3bn | USD 1.3bn | USD 1.4bn | +1.2% |
| Present Value Of The Forecast | USD 6.7bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 0.50% | CHF assumption - no free live source available for this market (assumption) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.798 | Reported 0.698, pulled toward 1.0 (Blume) |
| Cost of equity | 4.89% | Risk-free + beta x equity risk premium |
| Cost of debt | 2.50% | Implied cost of debt of 40.6% is not a credible funding cost, so risk-free + 2bp is assumed instead. Interest expense and reported debt are measuring different things - common for banks, whose interest expense includes deposits that total debt excludes. |
| Market capitalisation | USD 25.9bn | 98.1% of capital |
| Total debt | USD 509.0m | 1.9% of capital, book value as a proxy |
| Tax rate | 15.0% | Effective, capped at statutory |
| WACC | 4.83% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
86% of EV
- Forecast FCFF, final year
- USD 1.7bn
- Capex at depreciation, working capital in reinvestment
- USD 2.3bn
- Less reinvestment at g/ROIC (51.7% of NOPAT)
- USD -1.2bn
- Capitalised
- USD 1.1bn
- ROIC (WACC floor)
- 4.8%
- Terminal value, undiscounted
- USD 48.9bn
- Terminal value, discounted
- USD 39.5bn
- Enterprise value
- USD 46.2bn
- Less net debt
- USD 509.0m
- Equity value
- USD 45.7bn
Exit at 9.8x EBITDA
80% of EV
- Terminal value, undiscounted
- USD 33.2bn
- Terminal value, discounted
- USD 26.9bn
- Enterprise value
- USD 33.5bn
- Less net debt
- USD 509.0m
- Equity value
- USD 33.0bn
Spread between methods: 32%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 2.83% | 208.80 | 265.62 | 491.05 | — | — |
| 3.83% | 119.82 | 122.67 | 127.29 | 136.87 | 173.67 |
| 4.83% | 91.23 | 91.62 | 92.01 | 92.40 | 92.78 |
| 5.83% | 74.67 | 74.98 | 75.28 | 75.59 | 75.90 |
| 6.83% | 62.99 | 63.24 | 63.49 | 63.75 | 64.00 |
Outlined: this model. Green text: above today's price of 65.29. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 6.1% | -2.5% | -8.5pp |
| EBIT margin | 11.5% | 6.2% | -5.3pp |
| Discount rate | 4.8% | 6.7% | +1.8pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.